Nordic Life Science News writes about Elicera's patent acquisition from Immunicum

January 5, 2022

Immunicum has announced to transfer its patent rights for modified adenovirus (patent US 9,017,672 B2) to Elicera Therapeutics.

Download attachment (pdf)https://nordiclifescience.org/immunicum-transfers-patent-rights-to-elicera/
< Back to press releases
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.